Hello guest, Register  |  Sign In
Virologica Sinica, 29 (4) : 218-227, 2014
Research Article
Immunogenicity and protective efficacy of recombinant M2e. Hsp70c (Hsp70359-610) fusion protein against influenza virus infection in mice
1. Avian Diseases Research Center, Faculty of Veterinary Medicine, University of Shiraz, Shiraz 71345-1731, Iran

2. Department of Clinical Studies, School of Veterinary Medicine, Shahrekord University, Shahrekord 88186/34141, Iran

3. Department of Biotechnology and Immunology, Razi Vaccine and Serum Research Institute RVSRI, Karaj 31975/148, Tehran, Iran
 Correspondence: hamidreza_attaran@yahoo.com
New strategies in vaccine development are urgently needed to combat emerging influenza viruses and to reduce the risk of pandemic disease surfacing. Being conserved, the M2e protein, is a potential candidate for universal vaccine development against influenza A viruses. Mycobacterium tuberculosis Hsp70 (mHsp70) is known to cultivate the function of immunogenic antigenpresenting cells, stimulate a strong cytotoxic T lymphocyte (CTL) response, and stop the induction of tolerance. Thus, in this study, a recombinant protein from the extracellular domain of influenza A virus matrix protein 2 (M2e), was fused to the C-terminus of Mycobacterium tuberculosis Hsp70 (Hsp70c), to generate a vaccine candidate. Humoral immune responses, IFN-γ-producing lymphocyte, and strong CTL activity were all induced to confirm the immunogenicity of M2e.Hsp70c (Hsp70359-610). And challenge tests showed protection against H1N1 and H9N2 strains in vaccinated groups. Finally these results demonstrates M2e.Hsp70c fusion protein can be a candidate for a universal influenza A vaccine.
Received: 18 Aug 2014  Accepted: 28 Apr 2014  Published online: 1 Aug 2014
Home |  Resources |  About Us |  Support |  Contact Us |  Privacy |  Powered by CanSpeed | 
Copyright © 2015 Virologica Sinica. All rights reserved